- |||||||||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo, Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka, Daiichi Sankyo
Review, Journal: Fixed Combination for the Treatment of Dyslipidaemia. (Pubmed Central) - Sep 16, 2023 Lipid-lowering fixed-dose combinations may guarantee a higher therapy adherence, representing a better approach to control plasma lipids and thus ameliorate ASCVD burden. Additional studies will define the advantages on cardiovascular outcomes in high and very high-risk patients.
- |||||||||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo, Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka, Daiichi Sankyo
* Nexletol & Nexlizet (Twitter) - Mar 4, 2023
- |||||||||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka
Review, Journal: Bempedoic Acid: for Whom and When. (Pubmed Central) - Sep 20, 2022 Bempedoic acid does not lead to the risk of new-onset diabetes, and moderately improves the glycaemic profile. The extensive knowledge on bempedoic acid mechanism, metabolism and side effects has led to an improved understanding of the potential benefits of this agent and offers a possible alternative to cardiologists and clinical practitioners somewhat worn out today by the occurrence of the muscular side effects of statins.
- |||||||||| Journal: Lipid-lowering drugs. (Pubmed Central) - Sep 20, 2022
The extensive knowledge on bempedoic acid mechanism, metabolism and side effects has led to an improved understanding of the potential benefits of this agent and offers a possible alternative to cardiologists and clinical practitioners somewhat worn out today by the occurrence of the muscular side effects of statins. No abstract available
- |||||||||| Retrospective data, Review, Journal: Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol. (Pubmed Central) - Sep 11, 2022
Primary end point results were generally consistent at week 24, and for other lipid end points at week 12. Conclusions Evolocumab, 140 mg Q2W/420 mg once a month, and alirocumab, 150 mg Q2W, were consistently the most efficacious nonstatin regimens when added to maximally tolerated statins to lower LDL-C, non-high-density lipoprotein cholesterol, and apolipoprotein B levels and facilitate attainment of guideline-recommended risk-stratified lipoprotein levels.
- |||||||||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka
P3 data, Clinical Trial,Phase III, Journal: Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. (Pubmed Central) - Jun 22, 2022 In patients with hypercholesterolemia unable to take statins, bempedoic acid lowered LDL-C levels by a mean of 26.5% vs placebo and bempedoic acid + ezetimibe fixed-dose combination lowered LDL-C by 39.2%. The treatments were generally well tolerated, suggesting that bempedoic acid may be efficacious and well tolerated in this challenging-to-treat patient population.
- |||||||||| Leqvio (inclisiran) / Alnylam, Novartis
Journal: Inclisiran (Leqvio) for LDL-cholesterol lowering. (Pubmed Central) - Mar 23, 2022 The treatments were generally well tolerated, suggesting that bempedoic acid may be efficacious and well tolerated in this challenging-to-treat patient population. No abstract available
- |||||||||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka
[VIRTUAL] LS.10 Add on Efficacy: Oral, Nonstatin Therapies for Lowering LDL-C (Live) - Nov 9, 2021 - Abstract #AHA2021AHA_7612; The session will cover the following information:* Atherosclerotic cardiovascular disease and lipid management* Unique mechanism of action for two treatment options* Efficacy data for two treatment options* Safety data for two treatment options* Overview of the ongoing Outcomes trial -- Sponsored by: Esperion Therapeutics, Inc. -- Prescription Information: https://pi.esperion.com/nexlizet/nexlizet-pi.pdf --Prescription Information: https://pi.esperion.com/nexletol/nexletol-pi.pdf
- |||||||||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka
Review, Journal: Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia. (Pubmed Central) - Aug 1, 2021 Bempedoic acid is an additional treatment option, along with both statins and diet and exercise, for reducing cholesterol levels and ASCVD events. With the new FDA approval, bempedoic acid may offer an effective therapy for reducing low-density lipoprotein cholesterol in patients at high risk for cardiovascular events due to established ASCVD or heterozygous familial hypercholesterolemia.
- |||||||||| Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka
Journal: Quantitative observation of monochromatic X-rays emitted from implosion hotspot in high spatial resolution in inertial confinement fusion. (Pubmed Central) - Jul 16, 2021 Herein, the 8 ± 0.39-keV monochromatic X-ray distribution from the entire hotspot is quantitatively observed in 5-[Formula: see text]m spatial resolution using a Kirkpatrick-Baez microscope, with impacts from the responses of the diagnosis system removed, for the first time, in implosion experiments at the 100 kJ laser facility in China...Furthermore, the origins of the 17.81% contour profile of the deuterium-deuterium hotspot and the accurate Gaussian source approximation of the core emission area in the implosion capsule are clarified in detail. This work is significant for quantitatively exploring the physical conditions of the hotspot and updating the theoretical model of capsule implosion.
- |||||||||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka
[VIRTUAL] An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C presented by Esperion () - May 16, 2021 - Abstract #AACE2021AACE_179; This work is significant for quantitatively exploring the physical conditions of the hotspot and updating the theoretical model of capsule implosion. Sponsored By:Esperion, Nexletol, Nexlizet The session will cover the following information: Cardiovascular disease and its mortality and morbidity, unique mechanism of action for two treatment options, efficacy data for two treatment options, safety data for two treatment options, and an overview of the ongoing outcomes trial.
- |||||||||| Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka
Journal: X-SPEC: a 70 eV to 15 keV undulator beamline for X-ray and electron spectroscopies. (Pubmed Central) - Mar 3, 2021 The beamline is equipped with a permanent magnet undulator with two magnetic structures of different period lengths, a focusing variable-line-space plane-grating monochromator, a double-crystal monochromator and three Kirkpatrick-Baez mirror pairs...The first experimental station is optimized for measuring solid samples under ultra-high-vacuum conditions, while the second experimental station allows in situ and operando studies under ambient conditions. Measurement techniques include X-ray absorption spectroscopy (XAS), extended X-ray absorption fine structure (EXAFS), photoelectron spectroscopy (PES) and hard X-ray PES (HAXPES), as well as X-ray emission spectroscopy (XES) and resonant inelastic X-ray scattering (RIXS).
- |||||||||| Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka
Journal: Generation of an X-ray nanobeam of a free-electron laser using reflective optics with speckle interferometry. (Pubmed Central) - Feb 11, 2021 This problem is specifically disadvantageous for the Kirkpatrick-Baez (KB) mirror focusing system, in which a slight misalignment of ∼300 nrad can degrade the focused beam...It was verified that the KB mirror alignments were optimized with the required accuracy, and a focused vertical beam of 5.8 nm (±1.2 nm) was achieved after optimization. The speckle interferometry reported in this study is expected to be an effective tool for optimizing the alignment of nano-focusing systems and for generating an unprecedented intensity of up to 10 W cm using XFEL sources.
- |||||||||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka
Clinical, Journal: Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. (Pubmed Central) - Jan 13, 2021 P3 This review found bempedoic acid and ezetimibe significantly lowered lipid parameters, attenuated hsCRP levels, and had an acceptable safety profile for the treatment of hypercholesterolemia and ASCVD. The bempedoic acid and ezetimibe fixed-dose combination significantly lowered low-density lipoprotein cholesterol versus placebo or other oral monotherapies and had a favourable safety profile when added to maximally tolerated statin therapy in patients with hypercholesterolemia and high cardiovascular disease risk.
- |||||||||| Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka
Journal: Hard X-ray nano-holotomography with a Fresnel zone plate. (Pubmed Central) - Jan 2, 2021 Near-field holography, as one of the major phase contrast techniques, is often implemented using X-ray optics such as Kirkpatrick-Baez mirrors, waveguides and compound refractive lenses...The imaging quality of different types of Fresnel zone plates is compared in terms of the flat-field quality, the achievable resolution and exposure efficiency i.e. the photons arriving at the detector. Overall, this setup is capable of imaging different types of samples at high spatial resolution of below 100 nm in 3D with access to the quantitative phase information.
- |||||||||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka
Review, Journal: Bempedoic Acid: First Approval. (Pubmed Central) - Dec 31, 2020 Based on positive findings in the phase III CLEAR clinical trial programme, bempedoic acid has been approved in the USA and in the EU as monotherapy (NEXLETOL in the USA, Nilemdo in the EU) and as a fixed-dose combination with ezetimibe (NEXLIZET in the USA, Nustendi in the EU). This article summarizes the milestones in the development of bempedoic acid leading to these first approvals.
|